Table 1:
Baseline characteristics of the vancomycin started groups and overall population
| Variables* | Group | ||||
|---|---|---|---|---|---|
| V 111 | V 110 | V 101 | V 100 | Overall | |
| (N=240) | (N=88) | (N=38) | (N=48) | (N=427) | |
| Patient’s demographics | |||||
| Age | 54.0(16.2) | 57.1(18.6) | 58.3(13.6) | 57.1(12.5) | 55.0(16.3) |
| Sex - Male | 117(48.8%) | 48(54.5%) | 18(47.4%) | 18(37.5%) | 209(48.9%) |
| Race - White | 160(66.7%) | 49(55.7%) | 21(55.3%) | 19(39.6%) | 258(60.4%) |
| Medical conditions at or before index date | |||||
| Diabetes | 58(24.2%) | 23(26.1%) | 4(10.5%) | 9(18.8%) | 96(22.5%) |
| Renal Disease | 95(39.6%) | 45(51.1%) | 26(68.4%) | 39(81.3%) | 211(49.4%) |
| Chronic pulmonary disease | 128(53.3%) | 47(53.4%) | 24(63.2%) | 29(60.4%) | 237(55.5%) |
| Mild liver disease | 71(29.6%) | 23(26.1%) | 9(23.7%) | 10(20.8%) | 117(27.4%) |
| Moderate/Severe liver disease | 20(8.3%) | 8(9.1%) | 8(21.1%) | 4(8.3%) | 40(9.4%) |
| Cancer (any malignancy) | 31(12.9%) | 15(17.0%) | 7(18.4%) | 8(16.7%) | 62(14.5%) |
| Peripheral vascular disease | 100(41.7%) | 33(37.5%) | 24(63.2%) | 25(52.1%) | 183(42.9%) |
| Charlson’s Comorbidity Index | 5.80(3.65) | 6.52(4.48) | 8.50(3.75) | 7.42(3.30) | 6.35(3.88) |
| Evidence of antimicrobial resistance (infections prior to MRSA) | |||||
| Aminoglycosides | 33(13.8%) | 19(21.6%) | 13(34.2%) | 12(25.0%) | 79(18.5%) |
| Beta-lactams | 114(47.5%) | 42(47.7%) | 23(60.5%) | 28(58.3%) | 214(50.1%) |
| Carbapenems | 14(5.8%) | 7(8%) | 6(15.8%) | 6(12.5%) | 34(8%) |
| Fluoroquinolones | 55(22.9%) | 29(33.0%) | 19(50.0%) | 23(47.9%) | 130(30.4%) |
| Glycopeptides | 16(6.7%) | 7(8%) | 5(13.2%) | 7(14.6%) | 37(8.7%) |
| Polypeptides | 3(1.3%) | 1(1.1%) | 0(0%) | 1(2.1%) | 5(1.2%) |
| Sulfonamides | 54(22.5%) | 25(28.4%) | 14(36.8%) | 14(29.2%) | 111(26.0%) |
| Tetracyclines | 24(10.0%) | 13(14.8%) | 9(23.7%) | 8(16.7%) | 55(12.9%) |
| Multi-drug resistance (3+) | 66(27.5%) | 33(37.5%) | 21(55.3%) | 21(43.8%) | 147(34.4%) |
| Admission information | |||||
| ICU stay | 133(55.4%) | 37(42.0%) | 26(68.4%) | 25(52.1%) | 223(52.2%) |
| Healthcare acquired | 60(25.0%) | 13(14.8%) | 14(36.8%) | 15(31.3%) | 103(24.1%) |
| Days of admission | 20[10,392] | 19[10,115] | 19[10,1050] | 19[10,65] | 19[10,1050] |
| Outcome | |||||
| Death within 30 days | 11(4.6%) | 11(12.5%) | 5(13.2%) | 5(10.4%) | 33(7.7%) |
*
Mean(SD) or Median[Min,Max] or Count(%)